Spots Global Cancer Trial Database for saracatinib
Every month we try and update this database with for saracatinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | NCT00513071 | Hormone-resista... Recurrent Prost... | saracatinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung | NCT00752206 | Osteosarcoma | Saracatinib Placebo | 15 Years - 74 Years | Sarcoma Alliance for Research through Collaboration | |
| A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung | NCT00752206 | Osteosarcoma | Saracatinib Placebo | 15 Years - 74 Years | Sarcoma Alliance for Research through Collaboration | |
| Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer | NCT01196741 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Paclitaxel Saracatinib Matched placebo | 18 Years - | University College, London | |
| AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy | NCT00638937 | Recurrent Non-s... Stage IIIB Non-... Stage IV Non-sm... | saracatinib | 18 Years - | National Cancer Institute (NCI) | |
| Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer | NCT00718809 | Invasive Thymom... Recurrent Thymo... Stage III Thymo... Stage IVA Thymo... Stage IVB Thymo... | saracatinib | 18 Years - | National Cancer Institute (NCI) | |
| AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer | NCT00397878 | Adenocarcinoma ... Adenocarcinoma ... Recurrent Colon... Recurrent Recta... Stage IV Colon ... Stage IV Rectal... | saracatinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer | NCT00607594 | Adenocarcinoma ... Adenocarcinoma ... Recurrent Gastr... Stage III Gastr... Stage III Esoph... Stage IV Esopha... Stage IV Gastri... | saracatinib | 18 Years - | National Cancer Institute (NCI) | |
| Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer | NCT00735917 | Adenocarcinoma ... Recurrent Pancr... Stage IV Pancre... | saracatinib pharmacogenomic... pharmacological... positron emissi... fludeoxyglucose... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery | NCT00559507 | Estrogen Recept... Male Breast Can... Progesterone Re... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | saracatinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| SarCaBon: A Randomised Phase II Trial of Saracatinib Versus Placebo for Cancer-induced Bone Pain | NCT02085603 | Cancer | Saracatinib Placebo | 16 Years - | Sheffield Teaching Hospitals NHS Foundation Trust | |
| AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer | NCT00528645 | Extensive Stage... Lung Metastases Malignant Pleur... Recurrent Small... | saracatinib | 18 Years - | National Cancer Institute (NCI) | |
| Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis | NCT02737202 | Pulmonary Lymph... | saracatinib | 18 Years - 65 Years | Baylor College of Medicine |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
